Testing effectiveness (Phase 2)WithdrawnNCT02547961What this trial is testingChimeric Antigen Receptor-Modified T Cells for Breast CancerWho this might be right forBreast Cancer Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Study completedNCT03555877What this trial is testingAnti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerWho this might be right forBreast Cancer Metastatic GBG Forschungs GmbH 56
Testing effectiveness (Phase 2)Study completedNCT03112590What this trial is testingPhase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast CancerWho this might be right forBreast CancerBreast Cancer, MaleBreast Cancer Female+1 more H. Lee Moffitt Cancer Center and Research Institute 51
Testing effectiveness (Phase 2)Study completedNCT03839823What this trial is testingStudy to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 222
Not applicableStudy completedNCT02056080What this trial is testingClinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or LapatinibWho this might be right forBreast Neoplasm MedSIR 111
Early research (Phase 1)Ended earlyNCT05385705What this trial is testingAllogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020Who this might be right forBreast Neoplasms Vall d'Hebron Institute of Oncology 2
Testing effectiveness (Phase 2)Study completedNCT01783756What this trial is testingPhase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS MetastasisWho this might be right forCentral Nervous System MetastasesHER2-positive Breast CancerMale Breast Cancer+2 more Jonsson Comprehensive Cancer Center 9
Large-scale testing (Phase 3)Study completedNCT00667251What this trial is testingChemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 652
Testing effectiveness (Phase 2)Looking for participantsNCT05305924What this trial is testingFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerWho this might be right forER-Positive Breast CancerHER2-negative Breast Cancer The Methodist Hospital Research Institute 28
Large-scale testing (Phase 3)Active Not RecruitingNCT05063786What this trial is testingTrastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)Who this might be right forAdvanced Breast Cancer Spanish Breast Cancer Research Group 27
Large-scale testing (Phase 3)Active Not RecruitingNCT04739761What this trial is testingT-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerWho this might be right forBreast Cancer AstraZeneca 506
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726342What this trial is testingSMP-656 for HER2-Positive Advanced Breast CancerWho this might be right forHER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer (LABC) Chengdu SciMount Pharmatech Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT00475670What this trial is testingHerceptin (Trastuzumab) in Women With Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 44
Early research (Phase 1)Ended earlyNCT04060862What this trial is testingIpatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05810870What this trial is testingPIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinWho this might be right forBreast CancerAdvanced Breast CancerMetastatic Breast Cancer MedSIR 14
Testing effectiveness (Phase 2)Study completedNCT03659136What this trial is testingThe XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadWho this might be right forBreast Neoplasms Boehringer Ingelheim 103
Large-scale testing (Phase 3)Study completedNCT01810393What this trial is testingAssess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 YearsWho this might be right forBreast Cancer Hoffmann-La Roche 114
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934What this trial is testingPhase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Who this might be right forER-Positive HER2-Negative Breast Cancer AstraZeneca 315
Testing effectiveness (Phase 2)Study completedNCT00343109What this trial is testingVaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast CancerWho this might be right forHER2-positive Breast CancerMale Breast CancerStage IIIB Breast Cancer+2 more University of Washington 38
Large-scale testing (Phase 3)Study completedNCT05301010What this trial is testingClinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer PatientsWho this might be right forBreast Cancer MetastaticBreast Cancer RecurrentBreast Cancer Female Nanogen Pharmaceutical Biotechnology Joint Stock Company 128